ACTRN12619000990123进行中（未招募）2 期
An ALLG Window study of Acalbrutinib plus Rituximab followed by R-DHAOx+ASCT in fit Mantle Cell Lymphoma.
Australasian Leukaemia and Lymphoma Group0 个研究点目标入组 44 人开始时间: 2019年7月11日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 70 Years（—）
- 性别
- All
入选标准
- •1. Age 18 – 70 years
- •2. Histologically confirmed diagnosis of CD20 positive mantle cell lymphoma (MCL)
- •3. No prior lymphoma treatment including chemotherapy, radiotherapy or other investigational drug
- •4. Stage II-IV disease by Ann Arbor Criteria. Patients with stage I disease with bulk (greater than 7cms) that require systemic treatment will also be eligible. (must be able to undergo PET/CT imaging for staging purposes).
- •5. PET/CT avid disease at baseline.
- •6. Eastern Collaborative Oncology Group (ECOG) performance status 0, or 1, unless attributable to lymphoma in which case patients of performance status 2 are also eligible.
- •7. Adequate bone marrow function with haemoglobin greater than 80g/L, neutrophils greater than 1.0x109/L and platelets greater than 80x109/L at the time of study entry unless attributed to bone marrow infiltration by lymphoma.
- •8. Adequate renal function defined by an estimated creatinine clearance greater than or equal to 40 mL/min according to the Cockcroft-Gault formula (or local institutional standard method).
- •9. Adequate hepatic function defined by a total bilirubin level less than or equal to 2 × the upper limit of normal (ULN) range and AST and alanine aminotransferase (ALT) levels less than or equal to 3 × upper limit of institutional normal range unless attributed to lymphoma or Gilbert’s syndrome.
- •10. Patients must have an acceptable left ventricular ejection fraction (LVEF) i.e. within the local normal range for gated heart pool scan or echocardiogram
- •11. Life expectancy greater than 3 months.
- •12. Negative blood pregnancy test at screening for women of childbearing potential.
- •13. Signed written informed consent before any trial-related procedure is undertaken that is not part of the standard patient management.
排除标准
- •1. Any lymphoma not fulfilling the WHO diagnostic criteria1 for mantle cell lymphoma
- •2. Central nervous system involvement including meningeal involvement or cord compression from lymphoma
- •3. Subjects aged less than 18 or more than 70 years at screening
- •4. Subjects that are deemed not suitable for autologous stem cell transplant, in the opinion of the treating physician, at time of screening.
- •5. Subjects with a contraindication to study treatments
- •6. Prior organ transplantation, including allogeneic stem-cell transplantation
- •7. Prior malignancy, active within the previous 2 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast
- •8. Major surgery for any reason, except diagnostic biopsy, within 4 weeks of enrolment and/or if the subject has not fully recovered from the surgery within 4 weeks of enrolment
- •9. Past history of interstitial lung disease.
- •10. Any other serious active disease
- •11. Presence of human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS), Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening. Only patients who are HBV surface antigen (HBVsAg) and/or HBV core antibody (HBVcAb) positive are required to undergo HBV DNA PCR testing. Subjects that are HBV DNA negative who are HBVcAb positive are permitted in the study but must be on HBV prophylaxis.
- •12. Live vaccines within 30 days prior to the first dose of study drug and while participating in the study.
- •13. Uncontrolled AIHA (autoimmune hemolytic anaemia) or ITP (idiopathic thrombocytopenia pupura).
- •14. Suspicion of or confirmed progressive multifocal leukoencephalopathy
- •15. Has difficulty with or is unable to swallow oral medication, or significant gastrointestinal disease that would limit absorption of oral medication
- •16. Pregnant or lactating
研究者
相似试验
进行中（未招募）
2 期
Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell LymphomaMantle Cell LymphomaNCT04765111M.D. Anderson Cancer Center53
进行中（未招募）
1 期
Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin LymphomaNon Hodgkin LymphomaNCT02180711Acerta Pharma BV113
进行中（未招募）
3 期
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLLChronic Lymphocytic LeukemiaNCT02970318Acerta Pharma BV310
招募中
不适用
Acalabrutinib with rituximab and lenalidomide in relapsed/refractory B-cell non-Hodgkin lymphomaKCT0003724Seoul National University Hospital66
撤回
3 期
A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell LymphomaMantle Cell LymphomaNCT02735876Acerta Pharma BV